Mr. Goodman is the Co-Chair of the firm’s Commercial Litigation Group, a senior member of its White Collar & Regulatory Defense Group and the ...
Read Full Biography
Publications
-
2024 Private Equity Midyear Outlook
August 2024
Christopher Anthony
, Katherine Ashton
, Dominic Blaxill
, Ezra Borut
, Geoffrey P. Burgess
, Andrew J. Ceresney
, Christopher Dortschy
, Jane Engelhardt
, Andrew Ford
, Andrew J. Gershon
, Mark P. Goodman
, Jyotin Hamid
, Morgan J. Hayes
, Peter J. Irwin
, Eric T. Juergens
, Arian M. June
, Robert B. Kaplan
, M. Natasha Labovitz
, Andrew M. Levine
, Sidney P. Levinson
, Jonathan F. Lewis
, Gregory J. Lyons
, Timothy McIver
, Frank Mitchell
, Maura Kathleen Monaghan
, Edwin Northover
, Brett M. Novick
, Sheena Paul
, Marc Ponchione
, Ryan T. Rafferty
, Julie M. Riewe
, Paul D. Rubin
, Scott B. Selinger
, Thomas Smith
, Kristin A. Snyder
, Rick Sofield
, Katherine Durnan Taylor
, Ramya S. Tiller
, Jonathan R. Tuttle
, Patricia Volhard
, Erica S. Weisgerber
, Jennifer Wheater
, Naomi Aoyama
, Alison E. Buckley-Serfass
, Brett Adam Bush
, Zhiyan Cao
, Jennifer R. Cestaro
, Robert T. Dura
, Paul Eastham
, Stuart Hammer
, Lauren P. Heller
, Jin-Hyuk Jang
, Wen-Wei Lai
, Michael P. McGuigan
, Melissa Runsten
, Tricia Bozyk Sherno
, Jacob W. Stahl
, John Young
, Ulysses Smith
, Kayleigh Anderson
, Hymie A. Anteby
, Jabari Benjamin
, Charles Cartiglia
, Josephine Chen
, Jordan Corrente Beck
, Tejas N. Dave
, Julia Glazer
, Michael C. Godbe
, Zoe Jacoby
, Yiran Ji
, Adriana Kranjac
, Paul D. Lowry
, Kaitlyn McGill
, Diana Moise
, Amy Pereira
, John M. Satira
, Eike Björn Weidner
, Keith Moshe
-
Increased FCA Enforcement Targeting PE Firms Expected in 2024
11 March 2024
Helen V. Cantwell
, Courtney M. Dankworth
, Mark P. Goodman
, Maura Kathleen Monaghan
, Winston M. Paes
, Shannon Rose Selden
, Jacob W. Stahl
, Adam Aukland-Peck
, Kaitlyn McGill
-
Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
19 January 2024
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Melissa Runsten
, Jacob W. Stahl
, Adam Aukland-Peck
, Zoe Jacoby
, Adriana Kranjac
, Kaitlyn McGill
-
Top 10 Healthcare and Life Sciences Issues to Watch in 2024
4 January 2024
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Ted Hassi
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Michael Schaper
, Erica S. Weisgerber
, Kim T. Le
, Melissa Runsten
, Jacob W. Stahl
, Adam Aukland-Peck
, Ilya Balabanovsky
, Margaret Howard
, Chaim Lapp
, Hannah R. Levine
, Zoe Jacoby
, Kaitlyn McGill
-
CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
6 October 2023
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kim T. Le
, Jacob W. Stahl
, Hannah R. Levine
, Melissa Runsten
-
2023 Private Equity Midyear Outlook
27 July 2023
Christopher Anthony
, Katherine Ashton
, Dominic Blaxill
, Ezra Borut
, Geoffrey P. Burgess
, Andrew J. Ceresney
, Jeffrey P. Cunard
, E. Drew Dutton
, Jane Engelhardt
, Andrew Ford
, Andrew J. Gershon
, Mark P. Goodman
, Jyotin Hamid
, Ted Hassi
, Morgan J. Hayes
, Emily F. Huang
, Peter J. Irwin
, Eric T. Juergens
, Robert B. Kaplan
, Rafael Kariyev
, Meir D. Katz
, M. Natasha Labovitz
, Maurizio Levi-Minzi
, Andrew M. Levine
, Sidney P. Levinson
, Jonathan F. Lewis
, Timothy McIver
, Frank Mitchell
, Maura Kathleen Monaghan
, Edwin Northover
, Brett M. Novick
, Marc Ponchione
, Julie M. Riewe
, Shannon Rose Selden
, Steven J. Slutzky
, Thomas Smith
, Kristin A. Snyder
, J. Michael Snypes, Jr.
, Patrick Taylor
, Ramya S. Tiller
, Patricia Volhard
, Richard Ward
, Erica S. Weisgerber
, Alison E. Buckley-Serfass
, Brett Adam Bush
, Zhiyan Cao
, Robert T. Dura
, Stuart Hammer
, Megan McGuiggan
, Sheena Paul
, Tricia Bozyk Sherno
, Ulysses Smith
, Jacob W. Stahl
, Sergio Torres
, Jennifer Wheater
, Elie J. Worenklein
, Adam Aukland-Peck
, Colleen B. Bernaiche
, Charles Cartiglia
, Paul Eastham
, Jay E. Evans
, Sara Ewad
, Christopher Gossage
, Camila Isern
, Yiran Ji
, Maryam Kanna
, Rekha Korlipara
, Adriana Kranjac
, Samuel D. Krawiecz
, Harshil Mehta
, Gianni Pizzitola
, Stanley G. Seckler
, Sheng Shao
, Massy Vainshtein
-
New York Seeks Review and Approval Authority over Certain Healthcare Transactions
7 March 2023
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Kim T. Le
, Hannah R. Levine
-
Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
2 March 2023
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Kim T. Le
, Hannah R. Levine
-
Top 15 Healthcare and Life Sciences Issues to Watch in 2023
9 January 2023
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Michael Schaper
, Erica S. Weisgerber
, Kim T. Le
, Jacob W. Stahl
, Elie J. Worenklein
, Samuel J. Allaman
, Adam Aukland-Peck
, Hannah R. Levine
, Melissa Runsten
, Adam C. Saunders
, Adrian St. Francis
, Emily G. Dennan
, Micah A. Rubin
-
Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
November 2022
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kim T. Le
, Jacob W. Stahl
, Hannah R. Levine
-
Private Equity Report Fall 2022, Vol 22, No 3
November 2022
Andrew L. Bab
, Sally Bergmann Hardesty
, Michael Bolotin
, Jennifer L. Chu
, Erin Cleary
, Matthew Dickman
, Gregory V. Gooding
, Mark P. Goodman
, Gareth Hughes
, Mark Johnson
, Meir D. Katz
, Henry Lebowitz
, Maurizio Levi-Minzi
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kevin M. Schmidt
, Scott B. Selinger
, Ramya S. Tiller
, Zhiyan Cao
, Caroline P. Geiger
, Kim T. Le
, Jin-Hyuk Jang
, Tigist Kassahun
, Hannah R. Levine
, Keith J. Slattery
, Sergio Torres
, Dominique Trudelle
, Hadel Alfagir
, David N. Simpser
-
New York’s Adult Survivors Act to Take Effect on November 24, 2022
22 November 2022
Helen V. Cantwell
, Mark P. Goodman
, Jyotin Hamid
, Mary Beth Hogan
, Arian M. June
, Tricia Bozyk Sherno
-
Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
19 August 2022
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Kim T. Le
, Jacob W. Stahl
, Hannah R. Levine
-
Recent SCOTUS Decisions Impacting Healthcare
3 August 2022
Andrew L. Bab
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kim T. Le
, Jacob W. Stahl
, Adam Aukland-Peck
-
FTC Sharpens Focus on Private Equity
17 June 2022
Andrew L. Bab
, Mark P. Goodman
, Ted Hassi
, Maura Kathleen Monaghan
, Kevin Rinker
, Michael Schaper
, Erica S. Weisgerber
, Kim T. Le
, Leah Martin
, Adam C. Saunders
-
California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
16 June 2022
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Kim T. Le
, Jacob W. Stahl
, Hannah R. Levine
-
Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
1 March 2022
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kim T. Le
, Jacob W. Stahl
, Adam Aukland-Peck
, Adriana Kranjac
, Hannah R. Levine
, Melissa Runsten
-
The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
9 July 2021
Mark P. Goodman
, Maura Kathleen Monaghan
, Jim Pastore
, Jacob W. Stahl
, Adam Aukland-Peck
, Benjamin Leb
-
The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
12 March 2021
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Hannah R. Levine
, Melissa Runsten
, Benjamin Leb
-
Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
11 February 2021
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
Biden Takes Aim at Trump Administration Healthcare Policies
2 February 2021
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
30 December 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Kristin D. Kiehn
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
24 November 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
20 November 2020
Paul D. Rubin
, Melissa Runsten
, Kevin Rinker
, Andrew L. Bab
, Mark P. Goodman
, Maura Kathleen Monaghan
, Jennifer L. Chu
, Jacob W. Stahl
, Melissa Runsten
-
Federal Government Shines Spotlight on Speaker Programs
20 November 2020
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Kristin D. Kiehn
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
2 November 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Kevin Rinker
, Paul D. Rubin
, Maura Kathleen Monaghan
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
16 September 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
Senate Subcommittee Report Highlights Money Laundering and Sanctions Risks in the Art Industry
27 August 2020
Mark P. Goodman
, Satish M. Kini
, Andrew M. Levine
, William H. Taft V
-
HHS Announces Additional CARES Act Funding for Qualifying Providers
4 August 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Kim T. Le
, Melissa Runsten
-
Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
29 July 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
HHS Issues Additional Guidance on Qualifications for CARES Act Funding
8 May 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
Appropriations for Healthcare Providers Related to COVID-19
30 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
New Appropriation for Healthcare Providers
24 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
23 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
HHS Distributing $30 Billion in Grants to Medicare Providers
10 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
CMS Announces Intent to Provide $30 Billion to Medicare Providers
9 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
Update Regarding Public Health and Social Services Emergency Fund
6 April 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
30 March 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
CARES Act: Implications for Healthcare and Life Science Companies and Investors
27 March 2020
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
20 March 2020
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
17 March 2020
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
, Suchita Mandavilli Brundage
, Melissa Runsten
-
Ninth Circuit Decision Increases Risk of RICO Economic Loss Claims Against Pharmaceutical Manufacturers and Highlights Evolving Circuit Split
6 March 2020
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, J. Robert Abraham
-
What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
23 December 2019
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Ted Hassi
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Leah Martin
-
Delaware Court of Chancery Sustains Failure to Monitor Caremark Claim
22 October 2019
Mark P. Goodman
, Maura Kathleen Monaghan
, Jonathan R. Tuttle
, Paul D. Rubin
, Jacob W. Stahl
-
Life Science Leader: From Lab To Lawsuit: Litigation Risks In Pharma-Licensing Agreements
2 January 2019
Life Science Leader
Mark P. Goodman
, Henry Lebowitz
-
Affordable Care Act Likely to Survive Latest Challenge
19 December 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
How Life Sciences Companies Can Prepare For Legal And PR Crises
13 December 2018
Law360
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
-
How Life Sciences Cos. Can Prepare For Legal And PR Crises
December 13, 2018
Law360
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
-
Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
4 December 2018
Luke Dembosky
, Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
, Melissa Runsten
-
Managing the Minefield: How Life Sciences Companies Can Be Prepared for Legal and Public Relations Crises
30 November 2018
Mark P. Goodman
, Maura Kathleen Monaghan
, Paul D. Rubin
, Jacob W. Stahl
-
The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
9 November 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
5 November 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
23 October 2018
Andrew L. Bab
, David H. Bernstein
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
, Jared I. Kagan
, Melissa Runsten
-
The White House’s Drug Pricing “Blueprint”
18 May 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
DOJ Memorandum Addressing Agency Guidance
9 March 2018
Compliance & Enforcement
Courtney M. Dankworth
, Mark P. Goodman
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
DOJ Memorandum Addressing Agency Guidance
8 March 2018
Courtney M. Dankworth
, Mark P. Goodman
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
The Latest on the Trump Administration’s Drug Pricing Initiatives
21 February 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
DOJ Creates Potential Opening For Early Dismissal of False Claims Act Suits
1 February 2018
Mark P. Goodman
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
19 January 2018
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Melissa Runsten
, Jacob W. Stahl
-
How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
20 December 2017
Andrew L. Bab
, Jennifer L. Chu
, Peter A. Furci
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
20 December 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
Law360: How Tax Reform Could Impact the Health Care Industry
15 November 2017
Andrew L. Bab
, Jennifer L. Chu
, Peter A. Furci
, Mark P. Goodman
, Kevin Rinker
, Paul D. Rubin
, Jacob W. Stahl
-
How Tax Reform Could Impact The Health Care Industry
13 November 2017
Law360
Jennifer L. Chu
, Peter A. Furci
, Mark P. Goodman
, Paul D. Rubin
, Jacob W. Stahl
-
The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
7 November 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Gary M. Friedman
, Peter A. Furci
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Where Does Healthcare Reform Stand?
31 October 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
How Section 1332 Waivers Could Impact Health Care Reform
24 July 2017
Law 360
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Health Care Winners And Losers From The Better Care Act
29 June 2017
Law 360
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
The “Better Care Act”: Winners and Losers in the Healthcare Industry
28 June 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
The Senate’s Healthcare Bill – What’s In It?
28 June 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
5 May 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Shining A Light On GOP Plan For Health Care Reform
7 March 2017
Law360
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
27 February 2017
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Kevin Rinker
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
The Outlook For The Pharmaceutical Industry Under Trump
12 January 2017
Law360
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
The Outlook On Drug Pricing: At What Cost?
14 December 2016
Law360
Andrew L. Bab
, Jennifer L. Chu
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
15 November 2016
Andrew L. Bab
, Jennifer L. Chu
, Gary M. Friedman
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
, Jacob W. Stahl
-
A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent
7 October 2016
Bloomberg BNA Pharmaceutical Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Helen V. Cantwell
, Kristin D. Kiehn
, Jacob W. Stahl
-
New Federal Ransomware Guidance
19 July 2016
Luke Dembosky
, Mark P. Goodman
, Maura Kathleen Monaghan
, Jim Pastore
, David Sarratt
-
FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry
25 April 2016
Bloomberg BNA Health IT Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Jim Pastore
, David Sarratt
, Jacob W. Stahl
-
Florida Court Dismisses Data Breach Lawsuit for Lack of Standing
29 February 2016
Mark P. Goodman
, Maura Kathleen Monaghan
, Elliot Greenfield
, David Sarratt
-
FDA Publishes Guidance on Postmarket Cybersecurity Risk Management for Medical Device Manufacturers
25 January 2016
Mark P. Goodman
, Maura Kathleen Monaghan
, Jim Pastore
, David Sarratt
, Jacob W. Stahl
-
It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
12 January 2016
American Bar Association
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, Jacob W. Stahl
-
The “Yates Memorandum”: Has DOJ Really Changed Its Approach To White Collar Criminal Investigations and Individual Prosecutions?
15 September 2015
Helen V. Cantwell
, Matthew E. Fishbein
, Bruce E. Yannett
, David A. O'Neil
, Paul R. Berger
, Courtney M. Dankworth
, Eric Dinallo
, Mark P. Goodman
, Mary Beth Hogan
, Robert B. Kaplan
, Satish M. Kini
, Andrew M. Levine
, Michael B. Mukasey
, Jim Pastore
, Colby A. Smith
, Jonathan R. Tuttle
, Erich O. Grosz
, David Sarratt
-
Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies
10 July 2015
Bloomberg BNA Life Sciences Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, William H. Taft V
, Jacob W. Stahl
-
First Circuit Holds That Federal Law Preempts State-Law Claims Involving a Branded Drug Label
4 March 2015
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, J. Robert Abraham
-
Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
13 February 2015
Gary W. Kubek
, Mark P. Goodman
, Andrew L. Bab
, Maura Kathleen Monaghan
, Kevin Rinker
, Kristin D. Kiehn
, Erica S. Weisgerber
-
Breaking Ranks: Garlock Reaches Unprecedented Deal with Future Claims Representative on Value of Trust for Asbestos Claims
21 January 2015
Mark P. Goodman
, M. Natasha Labovitz
, Maura Kathleen Monaghan
, Shannon Rose Selden
-
Second Circuit Restores Teeth to Insider Trading Personal Benefit Requirement
11 December 2014
Paul R. Berger
, Helen V. Cantwell
, Eric Dinallo
, Matthew E. Fishbein
, Mark P. Goodman
, Matthew E. Kaplan
, Robert B. Kaplan
, Andrew M. Levine
, Jonathan R. Tuttle
, Bruce E. Yannett
-
Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures
14 November 2014
Bloomberg BNA’s White Collar Crime Report
Helen V. Cantwell
, Mark P. Goodman
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
14 November 2014
Bloomberg BNA’s Pharmaceutical Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, Jacob W. Stahl
-
The Shift in Litigation Risks When U.S. Companies Go Public
November 2014
Transaction Advisors
Mark P. Goodman
, Shannon Rose Selden
-
The Shift in Litigation Risks When U.S. Companies Go Public
Fall 2014
Mark P. Goodman
, Shannon Rose Selden
-
DOJ Proposal Shows Focus on Individuals in Corporate Crime
30 September 2014
Law360
Helen V. Cantwell
, Matthew E. Fishbein
, Mark P. Goodman
, Mary Beth Hogan
, Andrew M. Levine
, Jonathan R. Tuttle
, Bruce E. Yannett
, Kristin D. Kiehn
, David Sarratt
, Jacob W. Stahl
-
Provocative DOJ Proposal Aims to Hold Financial Services Executives Criminally Liable, Even Absent Criminal Intent
22 September 2014
Bruce E. Yannett
, Mary Beth Hogan
, Helen V. Cantwell
, Matthew E. Fishbein
, Mark P. Goodman
, Andrew M. Levine
, Jonathan R. Tuttle
, Kristin D. Kiehn
, Jacob W. Stahl
-
Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments
17 September 2014
Bloomberg BNA’s Health Care Fraud Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, Jacob W. Stahl
-
FDA Issues Proposed Guidance on Social Media and Internet Communications for Pharmaceutical and Medical Device Manufacturers
27 June 2014
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, Jacob W. Stahl
-
Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor
4 April 2014
Bloomberg BNA’s Pharmaceutical Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, Jacob W. Stahl
-
Court Rules that Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
February/March 2014
Pratt’s Journal of Bankruptcy Law.
Mark P. Goodman
, M. Natasha Labovitz
, Maura Kathleen Monaghan
-
Court Rules That Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
21 January 2014
Maura Kathleen Monaghan
, Mark P. Goodman
, M. Natasha Labovitz
-
Handling State AG Parens Patriae Actions Now That the Supreme Court Has Rejected Federal Court Removal
21 January 2014
Mark P. Goodman
, John S. Kiernan
, Maura Kathleen Monaghan
, Erica S. Weisgerber
-
Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications
20 December 2013
Bloomberg BNA Pharmaceutical Law & Industry Report
Mark P. Goodman
, Maura Kathleen Monaghan
, Jacob W. Stahl
-
Supreme Court to Review “Fraud on the Market” Presumption of Reliance in Securities Class Actions
21 November 2013
Mark P. Goodman
, John S. Kiernan
, Shannon Rose Selden
, William H. Taft V
, Gary W. Kubek
, Maeve O'Connor
, Colby A. Smith
-
Multi-Jurisdictional Criminal Investigations Pose Many Challenges
18 November 2013
New York Law Journal
Antoine F. Kirry
, Mark P. Goodman
, Frederick T. Davis
-
Did the Third Circuit Just Impose a Proof-of-Purchase Requirement in Consumer Product Class Actions?
6 August 2013
Mark P. Goodman
, Maura Kathleen Monaghan
-
Supreme Court Expands “Impossibility” Preemption to Design Defect Claims against Generic Drug Manufacturers
26 June 2013
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
, J. Robert Abraham
-
SEC Enforcement Action Targets Advisers to Private Equity Funds
15 March 2013
Paul R. Berger
, Kenneth J. Berman
, Jonathan R. Tuttle
, Eric Dinallo
, Mark P. Goodman
, Michael P. Harrell
, Shannon Rose Selden
-
Fund Directors Charged in Recent SEC Enforcement Case Targeting Valuation
14 December 2012
Paul R. Berger
, Jonathan R. Tuttle
, Eric Dinallo
, Mark P. Goodman
, Shannon Rose Selden
-
Second Circuit Concludes Truthful Off-Label Promotion Is Not Unlawful: Free Speech, But Not A Free Pass (Yet)
5 December 2012
Mark P. Goodman
, Maura Kathleen Monaghan
, Andrew M. Levine
, Kristin D. Kiehn
-
U.S. Enforcement Agencies Issue Extensive New FCPA Guidance
15 November 2012
Bruce E. Yannett
, Mark P. Goodman
, Andrew M. Levine
, Erich O. Grosz
, Paul R. Berger
, Colby A. Smith
, Jonathan R. Tuttle
, Philip Rohlik
-
GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements
August 2012
Rx Compliance Report
Kristin D. Kiehn
, Maura Kathleen Monaghan
, Mark P. Goodman
-
GSK $3 Billion Settlement Reflects Continued Expansion in Scope of Pharma Plea Agreements
9 July 2012
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
-
Supreme Court Upholds 2010 Patient Protection and Affordable Care Act
29 June 2012
Andrew L. Bab
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kevin Rinker
-
An Unprecedented Settlement For FDCA Violation
22 May 2012
Law360
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
-
Abbott Settlement Includes Unprecedented Term of Probation, Mandatory Compliance Measures
10 May 2012
Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
-
President Obama Signs the STOCK Act
4 April 2012
Eric Dinallo
, Mark P. Goodman
, Jennifer R. Cowan
-
Defending Corporations and Individuals in Government Investigations
2011 edition
Thomson West
Mark P. Goodman
-
Supreme Court Rules in Two Pharma Cases
29 June 2011
Anne E. Cohen
, Andrew L. Bab
, Kevin Rinker
, Mark P. Goodman
, Maura Kathleen Monaghan
, Kristin D. Kiehn
-
Bruesewitz v. Wyeth: Express Preemption Returns to the Fore
23 February 2011
Maura Kathleen Monaghan
, Roger E. Podesta
, Mark P. Goodman
, Anne E. Cohen
, Mary Beth Hogan
, Kristin D. Kiehn
-
U.S. Securities and Exchange Commission Launches Probe of Financial Institution Dealings with Sovereign Wealth Funds
18 January 2011
Paul R. Berger
, Bruce E. Yannett
, Eric Dinallo
, Mark P. Goodman
, Jonathan R. Tuttle
-
FCPA Update
December 2010, Vol. 2, No. 5
Paul R. Berger
, Bruce E. Yannett
, Mark P. Goodman
-
The Private Equity Report
Fall 2010
Franci J. Blassberg
, Guy Lewin-Smith
, Edwin Northover
, E. Drew Dutton
, Gary W. Kubek
, Kyra K. Bromley
, Marcia L. MacHarg
, Paul S. Bird
, Jonathan E. Levitsky
, Geoffrey Kittredge
, Mark P. Goodman
, Erica S. Weisgerber
, Jeffrey J. Rosen
, Peter A. Furci
-
U.S. Attorney’s Office for the Southern District of New York and U.S. Securities and Exchange Commission Investigate Massive Insider Trading Ring
22 November 2010
Mark P. Goodman
, Anne E. Cohen
, Helen V. Cantwell
, Jonathan R. Tuttle
-
The Private Equity Report
Summer 2009
Franci J. Blassberg
, Katherine Ashton
, Geoffrey P. Burgess
, Michael Diz
, Mark P. Goodman
, Richard F. Hahn
, Michael P. Harrell
, Satish M. Kini
, Paul L. Lee
, Jonathan F. Lewis
, Gregory J. Lyons
, Pierre Maugüé
, Jeffrey J. Rosen
-
Wyeth v Levine: The Road Ahead
3 April 2009
Scrip World Pharmaceutical News
Mark P. Goodman
, Maura Kathleen Monaghan
-
Wyeth v Levine: The Road Ahead
26 March 2009
ScripNews.com
Mark P. Goodman
, Maura Kathleen Monaghan
-
Courts Refuse to Give Full Faith and Credit to Nationwide Products Settlement
11 March 2009
Mark P. Goodman
, John S. Kiernan
-
Wyeth v. Levine: Not the End of Preemption and Not the End of the World
10 March 2009
Maura Kathleen Monaghan
, Roger E. Podesta
, Mark P. Goodman
, Anne E. Cohen
, Mary Beth Hogan
-
The Private Equity Report
Summer 2004
Franci J. Blassberg
, Carl Micarelli
, Mark P. Goodman
, David F. Hickok
, Richard Ward
, Rebecca F. Silberstein
, Marcia L. MacHarg
, Gregory V. Gooding
-
The Private Equity Report
Fall 2001
Mark P. Goodman
, Franci J. Blassberg
, William D. Regner
, Paul D. Brusiloff
, Adele M. Karig
, John M. Vasily
, Woodrow W. Campbell, Jr.
, Margaret Andrews Davenport
, Andrew N. Berg
-
Funding in Focus: When Healthcare Licensing Goes Wrong
Issue Seven, 2018
Mark P. Goodman
, Henry Lebowitz
, Megan K. Bannigan
, Jacob W. Stahl
View More Publications
Recent Events
-
Key Transactional, Legal & Regulatory Developments for Healthcare Investors
3 February 2022
Debevoise & Plimpton LLP
Webcast
Speaking Engagements
-
Leading Through a Corporate Crisis
11-12 September 2019
The Vanguard Network
The Vanguard Forum for General Counsels
New York, New York
Speaking Engagements
-
Pathway to the Boardroom
14 November 2018
PricewaterhouseCoopers
PwC's Pathway to the Boardroom
New York, New York
Speaking Engagements
-
Working with the Active Board of Today
8 November 2018
ExL Events Inc
Vanguard Healthcare Forum
New York, New York
Speaking Engagements
-
Developments in the Law of Legal Ethics in Internal Investigations: How to Best Protect Your Company in a Post-Financial Crisis World
4 June 2015
Debevoise Events
-
CIAs: What You Need to Consider
Eastern Standard Time
ACI
ACI’s 15th Advanced Forum on Fraud & Abuse in the Sales and Marketing of Medical Devices
Boston, Massachusetts
Speaking Engagements
View More Events